Continuing Medical Education (CME) Credits
Accreditation Statement
The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.
Designation Statement
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Target Audience
Anterior segment specialists with an interest in corneal refractive and cataract refractive surgery.
Educational Objectives
Upon completion of this program, participants should be able to:
- Discuss preoperative pearls, surgical techniques, and postoperative care for PRK, LASIK, and SMILE patients.
- Compare and contrast corneal refractive technologies.
- Examine advances in small aperture IOLs and discuss future treatment options for patients with irregular corneas.
- Discuss topical therapy treatments for presbyopia.
- Outline clear lens replacement strategies, including new technologies and advances in phakic IOLs and EDOF IOLs.
- Illustrate the refractive patient experience through surgical and pharmaceutical treatment strategies.
Claim CME/CE Credits
Attendees will be able to evaluate this webinar electronically. At the conclusion of the program, attendees follow the link to the program evaluation and credit claim. Please contact Janell John, ASCRS CME Coordinator, at jjohn@ascrs.org with any questions on credit claims.
Scientific Integrity and Financial Interest Disclosure
Financial Interest Disclosures for all faculty are available within the Financial Interest section of the Refractive Surgery: A Focus on Presbyopia and Precision website. ASCRS is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. ASCRS seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose all relevant financial interests. ASCRS has mechanisms in place to mitigate all conflicts of interest prior to an educational activity being delivered to learners.
All faculty members are required to disclose whether they, or their spouses, have any financial interest (or lack thereof) from the past 24 months with a company that produces, markets, resells or distribute ophthalmic products or services consumed by, or used on, patients. Faculty members are also required to disclose such information verbally and on their first slide.
It is an ASCRS requirement that all presenters disclose on the first slide and verbally at the beginning of any presentation whether they have any relevant financial interests from the past 24 months. Presenters are expected to give a fair and balanced presentation.
Financial Interest Disclosures
| CATEGORY | CODE | DESCRIPTION |
|---|---|---|
| Consultant/Advisor | C | I receive consultants fees or paid advisory boards, speakers bureaus or fees for attending a meeting from an Ineligible Entity or provide practice management/marketing services to ophthalmic practices (within the past 24 months). |
| Employee | E | I am a part-time or full-time employee of an Ineligible Entity (commercial interest) that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care. |
| Spouse/Partner | S | My spouse or partner has a financial relationship with an Ineligible Entity that produces, markets, resells or distributes ophthalmic products/devices/drugs or services related to patients clinical care- encompassing royalties, investment, consulting/speaker's bureau, research grants, travel reimbursement or employment. |
| Research/Grant Support | R | My research is fully or partially funded by an Ineligible Entity that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care. |
| Lecture Fees | L | My lecture fees (honoraria), travel fees or reimbursements when speaking at the invitation of an Ineligible Entity have been paid or subsidized by a company that produces, markets, resells or distributes ophthalmic products/devices/drugs or services related to patient care. |
| Product/Patent/Royalty | P | I earn a royalty or derive other financial gain from an ophthalmic product or service. |
| Equity Owner/Investor | O | I have an investment interest/equity ownership/stock options in a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs ore services related to patient clinical care. |
MODULE 1
Cathleen McCabe, MD is a consultant for Alcon; Allergan/Abbvie; Bausch + Lomb; Eyepoint Pharmaceuticals; Eyevance; Lensar; Novartis; Ocular Therapeutix; Omeros; Quidel; Science Based Health; Sight Sciences; Tarsus; Visus; and Zeiss. She receives lecture fees from Alcon; Allergan/Abbvie; Bausch + Lomb; Eyepoint Pharmaceuticals; Lensar; Ocular Therapeutix; Omeros; Sight Sciences; Tarsus; and Zeiss. She receives research support from Alcon; Allergan/Abbvie; Ocular Therapeutix; Orasis; and Surface Pharma.
Roger Zaldivar, MD is a consultant for Acufocus; J & J Vision; OCULENTIS; Physiol; Schwind; and Zeiss.
Vance Thompson, MD is a consultant for Acufocus; Alcon; Allergan; Allotex; Avellino; Bausch and Lomb; BVI; Carl Zeiss Meditec; Centricity; Euclid Systems; EyeGate Pharmaceuticals; FemtoVision; Forsight Robotics; Imprimis; iVeena; Johnson and Johnson; Leica; LensAR; Melt Pharmaceuticals; Ocular Innovations; ORA; Oyster Point Pharmaceuticals; ReFocus; RxSight; SightSciences; TearOptix; Treehouse Health; Visant; and Visus. He receives lecture fees from Acufocus; Alcon; and Johnson and Johnson. He is an investor in Acufocus; Optics; Allotex; Avellino; Centricity; Euclid Systems; EyeGate Pharmaceuticals; FemtoVision; Forsight Robotics; iVeena; Melt Pharmaceuticals; Ocular Innovations; Oyster Point Pharmaceuticals; RxSight; SightSciences; TearOptix; Treehouse Health; Visant; and Visus. He receives research support from Acufocus; Alcon; Allergan; Bausch and Lomb, ; BVI; Carl Zeiss Meditec; Centricity; EyeGate Pharmaceutical; Johnson and Johnson; Melt Pharmaceuticals; Ocular Therapeutix; ORA; Rayner; RxSight; SightSciences; and Visus.
Kathryn Hatch, MD is a consultant for Eyepoint; Eyevance; Johnson and Johnson; Kala Pharmaceuticals; Oyster Point; and Zeiss. She receives a royalty from LENZ. She receives research support from Alcon.
Julie Schallhorn, MD is a consultant for Allergan and Zeiss.
John Marshall, MD is a consultant for Avedro and Avellino. He receives lecture fees from Avedro; Avellino; and Zeiss. He is an investor in Avedro and Avellino. He receives royalties from Avedro. His spouse/partner has a financial relationship with Avedro and Avellino.
John Cason, MD has no relevant financial interests.
Marcony Santhiago, MD is a consultant for ZIEMER. He receives lecture fees from ALCON.
Luke Rebenitsch, MD is a consultant for Carl Zeiss Meditec and Staar Surgical. He is an investor in OSRx Pharmaceuticals.
Edward Manche, MD is a consultant for Avedro and Johnson and Johnson. He is an investor in RxSight. He receives research support from Alcon; Avedro; Carl Zeiss Meditec; Johnson and Johnson; Novartis; and Presbia.
Ronald Krueger, MD is a consultant for Alcon. He is an investor in Rx Sight. He receives research support from Alcon and Bausch Health.
Marguerite McDonald, MD is a consultant for Alcon; Allergan; Bausch; J & J Visioin; KALA; OCULUS USA; Quidel; Scope Ophthalmics; STROMA; SUN Pharma; and TearLab.
William Wiley, MD is a consultant for Alcon; Allergan; B&L; BVI; Imprimis; Ivantis; JNJ; Lensar; Rayner; RxSight; Sightlife; and Zeiss. He receives lecture fees from BVI; Imprimis; JNJ; Rayner; and Zeiss. He receives royalties from Imprimis. He receives research support from Alcon; B&L; Ivantis; RxSight; and Zeiss.
Maria Ravn, ASCRS Staff, has no relevant financial interests.
Carrie Braden, ASCRS Staff, has no relevant financial interests.
Janell John, ASCRS Staff, has no relevant financial interests.
All of the relevant financial relationships list for these individuals have been mitigated.
MODULE 2
Cathleen McCabe, MD is a consultant for Alcon; Allergan/Abbvie; Bausch + Lomb; Eyepoint Pharmaceuticals; Eyevance; Lensar; Novartis; Ocular Therapeutix; Omeros; Quidel; Science Based Health; Sight Sciences; Tarsus; Visus; Zeiss. She receives lecture fees from Alcon; Allergan/Abbvie; Bausch + Lomb; Eyepoint Pharmaceuticals; Lensar; Ocular Therapeutix; Omeros; Sight Sciences; Tarsus; Zeiss. She receives research support from Alcon; Allergan/Abbvie; Ocular Therapeutix; Orasis; Surface Pharma.
Roger Zaldivar, MD is a consultant for Acufocus; J & J Vision; OCULENTIS; Physiol; Schwind; and Zeiss.
Eric Donnenfeld, MD is a consultant for Aeon; Allergan; Avellino Labs; Bausch & Lomb; BVI; ELT Sight; Johnson & Johnson; Kala; Lensgen; Novartis; Oculis; Omega Ophthalmics; Oyster Point; Tearlab; Tearscience; Visus; Zeiss. He receives lecture fees from Johnson & Johnson and Novartis. He is an investor in Aeon; Avellino labs; ELT sight; kala; Lensgen; Oculis; Omega Ophthalmics; Oyster Point; Tearscience and Visus. He receives research support from Alcon; Allergan; Avellino labs; Johnson & Johnson; Kala; Novartis; Oculis and Tearscience.
Preeya Gupta, MD is a consultant for Alcon; Aldeyra; Allergan; Azura; Expert Opinion; HanAll Biopharma; J&J Vision; Kala; New World Medical; Novartis; Ocular Science; Ocular Therapeutix; Orasis; Oyster Point; Sight Sciences; Spyglass; Sun Pharmaceuticals; Surface Ophthalmics; Tear Clear; Tear Lab; Tissue Tech, Inc; Visionology; Zeiss. She is an investor in Azura; Expert Opinion; Orasis; Oyster Point; Spyglass; Surface Ophthalmics; Tarsus; Tear Clear; Visant; Visionology.
Jay Pepose, MD is a consultant for Acufocus; Allergan; Eyevance; JNJ Vision; Novartis; Thea Pharma. He is an investor in Azura.
Marguerite McDonald, MD is a consultant for Alcon; Allergan; Bausch; J & J Visioin; KALA; OCULUS USA; Quidel; Scope Ophthalmics; STROMA; SUN Pharma; TearLab.
Neda Shamie, MD is a consultant for and investor in Visus.
Kerry Solomon, MD is a consultant for alcon; cvc capitol partners; johnson and johnson vision; rayner; rx sight; zeiss. He receives lecture fees from alcon; zeiss. He is an investor in johnson and johnson vision; rayner; rx sight; tearlab.
Daniel Chang, MD is a consultant for Allergan; Carl Zeiss Meditec; Johnson & Johnson Vision; Omega Ophthalmics. He receives lecture fees from Allergan; Carl Zeiss Meditec; Johnson & Johnson Vision. He is an investor in Omega Ophthalmics.
Jack Holladay, MD is a consultant for Acufocus; Alcon; Clerio; M&S Technologies; Oculus; Ocuphire; Zeiss.
Vance Thompson, MD is a consultant for Acufocus; Allergan; Visant; Visus. He receives lecture fees from Acufocus. He is an investor in Acufocus; Visant; and Visus. He receives research support from Acufocus; Allergan; and Visus.
Nicole Fram, MD is a consultant for Allergan; Orasis Pharmaceuticals, LTD. She receives lecture fees from Novartis Pharma AG.
John Vukich, MD is a consultant for AcuFocus.
Amar Agarwal, MD has no relevant financial interests.
Maria Ravn, ASCRS Staff, has no relevant financial interests.
Carrie Braden, ASCRS Staff, has no relevant financial interests.
Janell John, ASCRS Staff, has no relevant financial interests.
All of the relevant financial relationships list for these individuals have been mitigated.
Notice About Off-Label Use Presentations
The webinar may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.